论文部分内容阅读
AIM:To determine the effects of pentoxifylline(PTX) on clinical manifestations and evaluate arterial blood gas data in hepatopulmonary syndrome(HPS) in children.METHODS:In a pilot study of 10 children with chronic liver disease,who had HPS,20 mg/kg/d PTX was administered for 3 mo.Clinical data and arterial blood gas parameters were evaluated at baseline,the end of the treatment period,and 3 mo after drug discontinuation.RESULTS:Six patients could tolerate PTX,while four patients experienced complications.Among patients who could tolerate PTX,there was a significant increase in arterial oxygen pressure(PaO 2)(P = 0.02) and oxygen saturation(SaO 2)(P = 0.04) and alveolar-arterial oxygen gradient(P = 0.02) after 3 mo of treatment.Significant decreases in PaO 2(P = 0.02) and alveolararterial oxygen gradient(P = 0.02) were also seen after drug discontinuation.CONCLUSION:PTX may improve PaO 2,SaO 2 and alveolar-arterial oxygen gradient in the early stage of HPS.
AIM: To determine the effects of pentoxifylline (PTX) on clinical manifestations and evaluate arterial blood gas data in hepatopulmonary syndrome (HPS) in children. METHODS: In a pilot study of 10 children with chronic liver disease, who had HPS, 20 mg / kg / d PTX was administered for 3 mo. Clinical data and arterial blood gas parameters were evaluated at baseline, the end of the treatment period, and 3 months after drug discontinuation. RESULTS: Six patients could tolerate PTX, while four patients experienced complications. Among the patients who could tolerate PTX, there was a significant increase in arterial oxygen pressure (PaO 2) (P = 0.02) and oxygen saturation (SaO 2) (P = 0.04) and alveolar-arterial oxygen gradient (P = 0.02) and also seen after drug discontinuation. CONCLUSION: PTX may improve PaO 2, SaO 2 and alveolar-arterial oxygen gradient in the early stage of HPS.